Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

April 30, 2021

Conditions
Ovarian Sex-cord Stromal Tumor
Interventions
DRUG

Paclitaxel

DRUG

Bevacizumab

Trial Locations (24)

13009

Institut Paoli Calmettes, Marseille

14076

Centre François Baclesse, Caen

21079

Centre Georges François Leclerc, Dijon

22190

Centre CARIO - HPCA, Plérin

25030

Hôpital Jean Minjoz, Besançon

31059

Institut Claudius Regaud, Toulouse

33076

Institut Bergonié, Bordeaux

34298

ICM Val d'Aurelle, Montpellier

44202

Hôpital Privé du Confluent, Nantes

44800

ICO Centre René Gauducheau, Saint-Herblain

51056

Institut Jean Godinot, Reims

54100

ORACLE - Centre d'Oncologie de Gentilly, Nancy

54511

ICL Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

63000

Centre Jean Perrin, Clermont-Ferrand

67200

Hôpitaux Universitaires de Strasbourg, Strasbourg

69373

Centre Léon Bérard, Lyon

75014

Hôpital Cochin, Paris

75020

Groupe Hospitalier Diaconesses - Croix Saint-Simon, Paris

Hôpital Tenon, Paris

76038

Centre Henri Becquerel, Rouen

86021

CHU de Poitiers - Hôpital de la Milétrie, Poitiers

94805

Gustave Roussy, Villejuif

Unknown

Polyclinique Bordeaux Nord, Bordeaux

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

ARCAGY/ GINECO GROUP

OTHER

NCT01770301 - Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) | Biotech Hunter | Biotech Hunter